AUS
NZ
UK
CA
USA
IND
Highlights
NanoViricides is a clinical-stage pharmaceutical company developing nanomedicine-based antivirals for emerging and existing infectious diseases
NV-387 exhibits broad antiviral effectiveness against pathogens including COVID-19, RSV, influenza, Mpox, and bird flu
The company is preparing regulatory filings for RSV treatment and is Phase II-ready for multiple viruses
NanoViricides operates within the biotechnology and pharmaceuticals sector, concentrating on the development of antiviral therapies through proprietary nanomedicine platforms. The company aims to offer first-in-class drugs capable of neutralizing a wide range of viral infections, using nanoviricide constructs that bind and dismantle viral particles, without requiring immune system intervention.
NV-387 Demonstrates Broad Antiviral Activity
NV-387, a lead drug candidate in the company’s pipeline, is under evaluation for its ultra-broad-spectrum antiviral capabilities. According to laboratory data, NV-387 shows activity against various pathogens including coronavirus, respiratory syncytial virus (RSV), influenza strains, Mpox, smallpox, and bird flu.
In comparative preclinical models, NV-387 has shown increased antiviral activity when measured against established influenza treatments such as Oseltamivir, Peramivir, and Baloxivir. In a model involving lethal lung infections, NV-387 significantly increased survival rates in treated groups.
Efficacy Across Multiple Infection Models
Preclinical studies have also explored NV-387’s effectiveness against orthopoxviruses using inhalation and skin exposure models. Tests involving Ectromelia virus in mice, which simulates Smallpox and Mpox in humans, indicated that NV-387 increased lifespan through oral administration. Results from these studies have demonstrated comparable outcomes to tecovirimat, the approved standard for Smallpox treatment.
Upcoming Regulatory Milestones for RSV Drug
NanoViricides is preparing for a pre-Investigational New Drug (pre-IND) submission to the United States Food and Drug Administration for NV-387 in the treatment of RSV. This indication is being developed for use in both pediatric and adult populations that currently have limited treatment options.
Additional Pipeline Candidates and Development Readiness
Beyond NV-387, the company is also advancing NV-HHV-101, a topical cream candidate for shingles rash. This formulation is Phase I-ready and is being designed to address infections related to varicella-zoster virus (VZV), herpes simplex virus type 1 (HSV-1), and type 2 (HSV-2).
Other assets in the pipeline include candidates aimed at addressing HIV/AIDS under the code NV-HIV-1, with additional virus-specific compounds in earlier stages of development.
Clinical Advancement Across Multiple Viral Families
NanoViricides’ clinical development portfolio includes drug candidates that are Phase II-ready for treatment of infections such as COVID-19, Mpox, Influenza including bird flu (H5N1), and RSV. The company’s approach emphasizes direct antiviral action that remains effective even as viral variants emerge.
Positioning Within Broader Healthcare and Small Cap Landscape
As a biotechnology entity with active drug development programs across multiple viral categories, NanoViricides contributes to the innovation stream tracked by the TSX small cap ETF, which includes healthcare and pharmaceutical innovators. The company’s emphasis on nanomedicine aligns with trends in the broader small cap index spotlighting high-impact research in therapeutic solutions.
